24th July 2008 - GlaxoSmithKline (GSK) and the Harvard Stem Cell Institute (HSCI) announced that they have entered into a five-year, $25 million-plus collaborative agreement to build a unique alliance in stem cell science, leading to the development of new medicines. GSK’s investment, one of the largest by a pharmaceutical company in stem cell science, will support innovative research at Harvard University and in at least four Harvard-affiliated hospitals in the areas of neuroscience, heart disease, cancer, diabetes, musculoskeletal diseases and obesity. In addition, GSK will fund an annual grant, which supports early stage research in stem cell biology, as part of HSCI’s seed grant program
This agreement marks the beginning of an exciting collaboration with multiple researchers at multiple Harvard institutions, making it possible for academic and industrial scientists to work side-by-side to develop treatments in areas of unmet medical need... GlaxoSmithKline's Press Release -
